Ladenburg Thalmann Reiterates Buy Rating, $24 PT for MAP Pharmaceuticals

In a company update published earlier today, Ladenburg Thalmann Financial Services reiterated its Buy rating and $24.00 price target for MAP Pharmaceuticals, Inc. MAPP. Ladenburg Thalmann said in its report “We remain positively biased towards Levadex [an inhaled version of the migraine treatment Dihydroergotamine] approval given the strong safety and efficacy data, MAPP's progress with the FDA in labeling discussions, and believe the CMC issues raised by the FDA will be addressed by MAPP and its manufacturer in a timely manner.” MAP Pharmaceuticals, Inc. closed on Friday at $12.10.